LivaNova (NASDAQ:LIVN) Stock Rating Raised to “Strong-Buy” at Barclays

Barclays upgraded shares of LivaNova (NASDAQ:LIVN) to a strong-buy rating in a report published on Wednesday,Zacks reports.

A number of other brokerages also recently commented on LIVN. Weiss Ratings upgraded LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 18th. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $85.00 target price on LivaNova in a research note on Wednesday, August 5th. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Needham & Company LLC boosted their price target on shares of LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $87.75.

LivaNova Stock Up 1.3%

LIVN stock opened at $75.93 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm has a 50-day moving average of $78.96 and a two-hundred day moving average of $74.91. LivaNova has a 12 month low of $48.82 and a 12 month high of $85.76. The company has a market cap of $4.18 billion, a price-to-earnings ratio of 22.46 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 EPS. As a group, analysts forecast that LivaNova will post 3.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director owned 4,434 shares in the company, valued at $345,896.34. This represents a 44.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,450 shares of company stock worth $591,839 over the last quarter. 0.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently modified their holdings of LIVN. Millennium Management LLC lifted its position in LivaNova by 17.3% in the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after acquiring an additional 514,268 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of LivaNova by 1,978.8% during the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after purchasing an additional 448,703 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of LivaNova during the first quarter worth about $18,327,000. Rhenman & Partners Asset Management AB increased its position in shares of LivaNova by 258.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock worth $11,691,000 after purchasing an additional 137,000 shares in the last quarter. Finally, Boone Capital Management LLC increased its position in shares of LivaNova by 72.0% during the fourth quarter. Boone Capital Management LLC now owns 288,895 shares of the company’s stock worth $17,776,000 after purchasing an additional 120,963 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.